secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2026-07-16T20:06:13+00:00
Accession:  0002007919-26-000037
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx expands credit facility to $500M with Oxford Finance, receives $100M upfront
--------------------------------------------------------------------------------

- Total facility expanded to $500M; $100M funded immediately as Term C Loan, up to $225M more at lenders' discretion.
- Prior to amendment, $175M had been drawn under the original facility.
- Issued warrants to purchase 21,457 shares at $93.21 per share in connection with Term C Loan.
- Proceeds to support clinical development of ozekibart (INBRX-109) and INBRX-106.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000037/0002007919-26-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000037/inhibrx-20260715.htm
  HTML page:      https://secwatch.observer/filing/0002007919-26-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer